Halma has announced the acquisition of French healthcare technology company Dreampath Diagnostics, strengthening its presence in the rapidly growing field of pathology laboratory automation. The deal marks another step in Halma's strategy to expand its healthcare portfolio with technologies that improve diagnostic efficiency and patient safety.

Under the agreement, Halma will pay an initial cash consideration of €154 million, with an additional performance-based earn-out of up to €121 million tied to Dreampath's financial performance through March 2028. Dreampath is expected to generate approximately €33 million in revenue during the 12 months ending March 2027.

Headquartered in Strasbourg, France, Dreampath develops automated hardware, software, and consumables that help anatomical pathology laboratories track, store, archive, and retrieve patient tissue samples throughout the diagnostic process. Its digital workflow solutions are designed to reduce manual errors, improve traceability, accelerate sample retrieval, and support more accurate laboratory operations. The company's technology is currently used by hundreds of laboratories across dozens of countries.

Halma said the acquisition complements its existing Healthcare Sector by adding advanced pathology workflow capabilities to its portfolio of diagnostic technologies. The company believes demand for efficient laboratory automation will continue to rise as healthcare systems face increasing testing volumes, aging populations, and a greater need for precision diagnostics.

Following the acquisition, Dreampath will continue to operate as a standalone business within Halma's Healthcare Sector under its current management team. Halma expects the company's expertise in digital pathology automation to create long-term value while supporting safer and more efficient diagnostic services for healthcare providers worldwide.

The acquisition also represents a successful exit for growth investment firm Summit Partners, which invested in Dreampath in 2025 to accelerate the company's international expansion, product development, and commercial growth. During Summit's investment period, Dreampath expanded its global footprint and strengthened its position as a provider of digital sample management systems for pathology laboratories.

With healthcare providers increasingly adopting automation and digital workflows, Halma's acquisition of Dreampath reinforces its commitment to delivering technologies that improve laboratory efficiency, diagnostic accuracy, and patient care while positioning the company for continued growth in the healthcare diagnostics market.